Sun Pharma Q3 net profit up 15%, board announces interim dividend

Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15% on-year to ₹2,903 crore in the December quarter, riding on robust sales across geographies.

The drug major had reported a net profit of ₹2,524 crore in the October-December quarter of last fiscal.

Total revenue from operations rose to ₹13,675 crore in the third quarter compared to ₹12,381 crore in the year-ago period, Sun Pharma said in a regulatory filing.

Interim Dividend announced

The company said its board has declared an interim dividend of ₹10.5 per share for the year FY25 against ₹8.50 per share interim dividend for the previous year.

"Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales," Sun Pharma Chairman and Managing Director Dilip Shanghvi said.

"Our market share gain in India has been driven by industry-leading volume growth. Emerging Markets demonstrated strong performance in spite of currency challenges across geographies," he added.

All the company's businesses remain well-positioned for the future, Shanghvi stated.

The Mumbai-based drug maker said its formulation sales in India stood at ₹4,300 crore in the December quarter, a growth of 13.8% over the same period last fiscal and accounting for around 32 per cent of total consolidated sales.

Formulation sales in the US were at $474 million for the third quarter, a marginal dip as compared with the third quarter of last fiscal and accounting for around 30% of the total consolidated sales.

Formulation sales in the emerging markets stood at $277 million in the third quarter, a year-on-year growth of 10% and accounting for around 17% of total consolidated sales.

Similarly, formulation sales in the Rest of World (ROW) markets, excluding India, the US and Emerging Markets, stood at $259 million in Q3FY25, a year-on-year growth of 21% against the preceding fiscal.

External sales of API (Active Pharmaceutical Ingredient) were Rs 568 crore in Q3FY25, growing by 21.8% over Q3 last year.

Sun Pharma shares ended 0.12% lower at ₹1,743.10 apiece on the BSE.